NanoVibronix effects 1-for-20 reverse stock split, reducing outstanding shares to ~1.64M

ENvue Medical, Inc.

Reverse split ratio 1-for-20 effective 4:05 p.m. ET on Feb 8, 2023; adjusted trading starts Feb 9.
Outstanding shares reduced from 32,894,359 to approximately 1,644,718, with fractional shares rounded up.
Authorized shares unchanged at 40M; par value remains $0.001 per share.
Proportional adjustments to equity awards, warrants, and convertible securities exercise prices and shares.
Stock symbol remains NAOV; new CUSIP 63008J603.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ENvue Medical, Inc.: Reverse stock split of common stock at a 1-for-20 ratio via Certificate of Amendment to Amended and Restated Certificate of Incorporation (effective 2023-02-08).

Change: charter amendment
Effective: 2023-02-08

Exact text from the filing

On February 8, 2023, NanoVibronix, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-20 reverse stock split of the shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), either issued and outstanding or held by the Company as treasury stock, effective as of 4:05 p.m. (Delaware time) on February 8, 2023 (the “Reverse Stock Split”).

View on SEC.gov

87 governance changes filed in the last 30 days. Browse all governance changes →

ENvue Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-003953

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.